Peptides for inhibiting chemokine binding to chemokine receptors

{
  "publication_number": "US8383769B2",
  "country": "US",
  "kind": "B2",
  "title": "Peptides for inhibiting chemokine binding to chemokine receptors",
  "abstract": "Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.",
  "claims": [
    "1. An isolated peptidic chemokine modulator comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 100, 96, 95, 46, 69, 79, 125, 87, 71, 5, 109, 19 and 57.",
    "2. The peptidic chemokine modulator of claim 1, being up to 20 amino acids in length.",
    "3. The peptidic chemokine modulator of claim 1, comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 100, 96, 95, 46 and 69.",
    "4. The peptidic chemokine modulator of claim 1, comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 79 and 125.",
    "5. The peptidic chemokine modulator of claim 1, comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 100, 96, 95, 46, 69, 79, 125 and 19.",
    "6. A composition comprising the peptidic chemokine modulator of claim 5, the composition being for inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is MIG (monokine induced by gamma interferon).",
    "7. The composition of claim 6, further comprising a pharmaceutically acceptable carrier.",
    "8. The composition of claim 7, wherein said carrier is for an administration selected from the group consisting of topical administration, inhalation, intranasal administration, and systemic administration.",
    "9. A method of inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is MIG (monokine induced by gamma interferon), the method comprising contacting the chemokine with an effective amount of the peptidic chemokine modulator of claim 5.",
    "10. The method of claim 9, wherein said peptide binds to said chemokine and directly inhibits a biological activity of said chemokine by inhibition of binding of said chemokine to said chemokine receptor.",
    "11. The peptidic chemokine modulator of claim 1, comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 96, 46, 5, 109, 19 and 57.",
    "12. A composition comprising the peptidic chemokine modulator of claim 11, the composition being capable of inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is MCP-1 (monocyte chemotactic protein-1).",
    "13. The composition of claim 12, further comprising a pharmaceutically acceptable carrier.",
    "14. The composition of claim 13, wherein said carrier is for an administration selected from the group consisting of topical administration, inhalation, intranasal administration, and systemic administration.",
    "15. A method of inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is MCP-1 (monocyte chemotactic protein-1), the method comprising contacting the chemokine with an effective amount of the peptidic chemokine modulator of claim 11.",
    "16. The method of claim 15, wherein said peptide binds to said chemokine and directly inhibits a biological activity of said chemokine by inhibition of binding of said chemokine to said chemokine receptor.",
    "17. The peptidic chemokine modulator of claim 1, comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 100, 69 and 19.",
    "18. A composition comprising the peptidic chemokine modulator of claim 17, the composition being capable of inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is interleukin 8.",
    "19. The composition of claim 18, further comprising a pharmaceutically acceptable carrier.",
    "20. The composition of claim 19, wherein said carrier is for an administration selected from the group consisting of topical administration, inhalation, intranasal administration, and systemic administration.",
    "21. A method of inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is interleukin 8, the method comprising contacting the chemokine with an effective amount of the peptidic chemokine modulator of claim 17.",
    "22. The method of claim 21, wherein said peptide binds to said chemokine and directly inhibits a biological activity of said chemokine by inhibition of binding of said chemokine to said chemokine receptor.",
    "23. The peptidic chemokine modulator of claim 1, comprising a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 95 and 87.",
    "24. A composition comprising the peptidic chemokine modulator of claim 23, the composition being capable of inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is eotaxin.",
    "25. The composition of claim 24, further comprising a pharmaceutically acceptable carrier.",
    "26. The composition of claim 25, wherein said carrier is for an administration selected from the group consisting of topical administration, inhalation, intranasal administration, and systemic administration.",
    "27. A method of inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is eotaxin, the method comprising contacting the chemokine with an effective amount of the peptidic chemokine modulator of claim 23.",
    "28. The method of claim 27, wherein said peptide binds to said chemokine and directly inhibits a biological activity of said chemokine by inhibition of binding of said chemokine to said chemokine receptor.",
    "29. The peptidic chemokine modulator of claim 1, comprising a peptide comprising the amino acid sequence SEQ ID NO:96.",
    "30. A composition comprising the peptidic chemokine modulator of claim 29, the composition being capable of inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is SDF-1α (stromal cell-derived factor-1α).",
    "31. The composition of claim 30, further comprising a pharmaceutically acceptable carrier.",
    "32. The composition of claim 31, wherein said carrier is for an administration selected from the group consisting of topical administration, inhalation, intranasal administration, and systemic administration.",
    "33. A method of inhibiting the binding of a chemokine to a chemokine receptor, wherein said chemokine is SDF-1α, the method comprising contacting the chemokine with an effective amount of the peptidic chemokine modulator of claim 29.",
    "34. The method of claim 33, wherein said peptide binds to said chemokine and directly inhibits a biological activity of said chemokine by inhibition of binding of said chemokine to said chemokine receptor.",
    "35. An isolated peptidic chemokine modulator comprising a peptide comprising the amino acid sequence SEQ ID NO:71.",
    "36. A composition comprising the peptidic chemokine modulator of claim 35, the composition being capable of enhancing the binding of a chemokine to a chemokine receptor, wherein said chemokine is SDF-1α.",
    "37. The composition of claim 36, further comprising a pharmaceutically acceptable carrier.",
    "38. The composition of claim 37, wherein said carrier is for an administration selected from the group consisting of topical administration, inhalation, intranasal administration, and systemic administration.",
    "39. A method of enhancing the binding of a chemokine to a chemokine receptor, wherein said chemokine is SDF-1α, the method comprising contacting the chemokine with an effective amount of the peptidic chemokine modulator of claim 35.",
    "40. The method of claim 39, wherein said peptide binds to said chemokine and directly enhances a biological activity of said chemokine by enhancing binding of said chemokine to said chemokine receptor."
  ],
  "description_excerpt": "The present invention discloses novel peptidic molecules or peptidomimetic agents, which are capable of binding chemokines and modulating their biological functions.\n\nDrug discovery in the post-genomics era provides enormous opportunities as well as new challenges. The targets of the drug discovery process have changed greatly over the last 50 years. The development of advanced purification technologies and the tools of molecular biology have brought molecular targets into the current discovery process. In the last ten years, there has been a trend towards selecting molecular targets for the screening process, and the human and other genome projects have made available many thousands of additional targets for drug discovery. In addition to these novel targets with unknown potential, there are a significant number of well-validated targets associated with major human diseases. Most of these are either nuclear receptors or G protein-coupled receptors. It was found, that in some cases, one compound that has an effect through one receptor, can also act through another receptor, and that several compounds can work through the same receptor. Unfortunately, even when the mechanism of a disease process is understood, for example by identifying the receptor(s) responsible for such a process, this information has not always resulted in the development of new treatments. For example, subjects who suffer from inflammation associated diseases and disorders have a great and desperate demand for novel drugs as therapeutic agents. Current therapies are merely palliative and have not been significantly improved in recent years.",
  "cpc": [
    "A61K 38/10",
    "A61K 38/00",
    "A61K 38/08",
    "A61K 39/00",
    "A61P 17/06",
    "A61P 19/02",
    "A61P 29/00",
    "A61P 3/10",
    "A61P 31/04",
    "A61P 31/12",
    "A61P 35/00",
    "A61P 37/06",
    "A61P 37/08",
    "A61P 9/10",
    "A61P 9/12",
    "B65G 11/023",
    "B65G 11/163",
    "C07K 7/08",
    "C07K 7/64"
  ],
  "ipc": [
    "A61K 38/00",
    "A61K 38/04",
    "A61K 38/08",
    "A61K 39/00",
    "A61K 45/00",
    "B65G 11/02",
    "B65G 11/12",
    "B65G 11/16",
    "C07K 7/08",
    "C07K 7/64"
  ],
  "assignees": [
    "BIOKINE THERAPEUTICS LTD",
    "PELED AMNON",
    "EIZENBERG ORLY",
    "VAIZEL-OHAYON DALIT"
  ],
  "inventors": [
    "PELED AMNON",
    "EIZENBERG ORLY",
    "VAIZEL-OHAYON DALIT"
  ],
  "filing_date": "2011-10-17",
  "publication_date": "2013-02-26",
  "grant_date": "2013-02-26",
  "priority_date": "2002-02-28",
  "application_number": "US-201113274478-A",
  "family_id": "27766173",
  "citations": [
    "US2003027751A1",
    "US2003166004A1",
    "US2004171552A1",
    "US2010173848A1",
    "US5840693A",
    "WO02061087A2",
    "WO03072599A2"
  ]
}